Lexicon Genetics Inc.

Lexicon Genetics (NASDAQ: LEXG) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease.
www.lexicon-genetics.com

  

News

Stem Cell Sciences Grants Lexicon Genetics Exclusive IRES Licence

🕔11/4/2005 10:55:28 AM 1790

The board of Biotech Capital (ASX: BTC) announced that its investee company (Stem Cell Sciences plc ("SCS") has concluded an agreement with the US-Based company Lexicon Genetics ("Lexicon"). Lexicon is a biopharmaceutical company focused on the discovery and development of treatments for a range of human diseases primarily using its proprietary gene knock out technology.

Read Full Article
###

1,116 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 23) (Since Published: 1116) 

Company Data

Social Media